Checkpoint Therapeutics Cash Flow Statement

Financials in millions INR. Fiscal year is April - March.

Millions INR. Fiscal year is Apr - Mar.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Net Income	18.9	41.97	39.46	18.01
Depreciation & Amortization	2.53	9.62	0.96	0.37
Other Operating Activities	2.09	-3.05	11.65	6.92
Change in Accounts Receivable	5.98	-9.96	-46.34	-44.81
Change in Inventory	-17.04	-42.68	-4.27	-42.07
Change in Accounts Payable	-0.99	-2.71	1.5	7.62
Change in Other Net Operating Assets	31.87	-181.24	-28.32	-15.52
Operating Cash Flow	43.34	-188.06	-25.36	-69.48
Capital Expenditures	-6.37	-51.31	-0.34	-8.91
Investing Cash Flow	-46.92	-51.31	-0.34	-8.91
Short-Term Debt Issued	-	-	33.76	-
Total Debt Issued	-	-	33.76	12.58
Short-Term Debt Repaid	-5.48	-25.06	-	-
Total Debt Repaid	-5.48	-25.06	-	-
Net Debt Issued (Repaid)	-5.48	-25.06	33.76	12.58
Issuance of Common Stock	-	276.15	-	74.57
Common Dividends Paid	-2.07	-	-	-
Other Financing Activities	-1.72	-0.83	-0.67	-0.71
Financing Cash Flow	-9.27	250.26	33.09	86.44
Miscellaneous Cash Flow Adjustments	-	-0	0.2	-
Net Cash Flow	-12.84	10.89	7.59	8.06
Free Cash Flow	36.98	-239.36	-25.7	-78.39
Free Cash Flow Margin	34.30%	-188.75%	-22.57%	-125.31%
Free Cash Flow Per Share	1.78	-12.69	-2.07	-
Cash Interest Paid	1.72	0.89	0.67	0.71
Cash Income Tax Paid	9.02	22.16	4.05	-
Levered Free Cash Flow	33.67	-238.11	-15.01	-
Unlevered Free Cash Flow	34.74	-237.61	-14.61	-
Change in Net Working Capital	-19.81	234.5	49.7	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.